Tyligand Bioscience Presents Preclinical Data on FDA IND-Cleared KRAS G12D Inhibitor TSN1611 at the 2024 AACR Annual Meeting

April 5, 2024 – Tyligand Bioscience, a clinical-stage biotechnology company dedicated to developing innovative therapies for drug-resistant tumors, presented the preclinical research results of its independently developed KRAS G12D inhibitor TSN1611 (Poster #3315) at the American Association for Cancer Research (AACR) Annual Meeting.  

TSN1611 is a highly potent and selective small molecule drug independently developed by Tyligand Bioscience targeting tumors harboring the KRAS G12D mutation, a key driver in the progression of various malignancies. The oral formulation of TSN1611 has been cleared by the U.S. Food and Drug Administration (FDA) for clinical trials, marking a significant step in the development of this potential therapy.  

"Preclinical studies indicate that TSN1611 has the potential to improve the current treatment landscape for patients with KRAS G12D-mutant tumors. We are excited to share our findings with the scientific and medical communities," said Dr. Tony Zhang, Chief Executive Officer of Tyligand Bioscience. "We are committed to advancing the development of this drug with full speed and high quality, with the hope of benefiting cancer patients worldwide as early as possible."  

KRAS mutations are among the most common oncogenic mutations, and targeting the most prevalent G12D mutation remains highly challenging. Despite significant advances in cancer research and treatment in recent years, KRAS-driven tumors continue to present a substantial unmet medical need, highlighting the urgency for innovative therapeutic options.  

The data presented at the 2024 AACR Annual Meeting demonstrates TSN1611's favorable druggability in inhibiting the KRAS G12D target, as well as its in vivo efficacy and safety in animal models. The FDA IND clearance represents a crucial step forward in the clinical evaluation of its safety and efficacy.